Over 5,000 testosterone therapy product liability ads ran on television in February following the FDA's announcement of an investigation into possible health risks associated with the drugs. 

This advertising blitz and the recent appearance of lawsuits against the manufacturers of these drugs signals the coming of protracted and widespread multidistrict and mass tort litigation over these products.

Estimated spending on these ads increased by nearly 1200% over spending in January at $1.7M.

Most of the TV ads referred to testosterone treatments generally -- although some mentioned the market leader AndroGel (AbbVie) and Axiron (Lilly) by name.